Palmitoyl Tripeptide-38 vs Palmitoyl Hexapeptide-12
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Matrixyl synthe'6, Matrixyl Synthe 6
Palmitoyl tripeptide-38 is the active in Sederma's Matrixyl synthe'6, a newer member of the Matrixyl family launched around 2011. It is a three-amino-acid fragment with a fatty acid tail, sold as a wrinkle 'filler from the inside' for forehead lines and crow's feet. It is a cosmetic ingredient, not a drug, and the honest picture is simple: the efficacy claims come almost entirely from the company that makes it.
Also: Biopeptide EL, Pal-VGVAPG
Palmitoyl hexapeptide-12 is the six-amino-acid sequence VGVAPG, a repeating piece of elastin, with a fatty acid tail attached so it can get into skin. It is sold under the trade name Biopeptide EL and pitched for firmness and elasticity, the bounce-back that fades with age. It is a cosmetic ingredient, not an FDA-approved drug, and nobody has published an independent clinical trial showing it visibly changes skin.
Key Comparison Insights
- Both peptides belong to the Skin & Hair category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Palmitoyl Tripeptide-38 | Palmitoyl Hexapeptide-12 |
|---|---|---|
| Category | Skin & Hair | Skin & Hair |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | The peptide is Pal-Lys-Met(O2)-Lys: lysine, an oxidized methionine (methionine sulfone) and lysine, with a palmitic acid chain attached so it can get into the outer skin more easily. The sequence is taken from connective tissue proteins (collagen VI and laminin), and the idea is the classic 'matrikine' story: small fragments of broken-down matrix proteins act as a signal telling skin cells to make more matrix. Sederma claims it boosts six components in lab tests, which is where the 'synthe'6' name comes from: collagen I, III and IV, fibronectin, hyaluronic acid and laminin-5. That is a plausible signaling mechanism, but it rests on cell culture work by the manufacturer. Whether enough peptide reaches the dermis in real skin to make a measurable difference has not been independently shown. | VGVAPG repeats many times in elastin, the protein that lets skin snap back. When elastin breaks down, fragments like this are released, and back in 1984 researchers showed VGVAPG attracts fibroblasts and monocytes in the lab, which is the basis for calling it a matrikine: a matrix fragment that tells repair cells to show up and get to work. The palmitoyl tail makes the peptide fat-friendly enough to cross the outer skin layer. A 2025 ex vivo study added a twist: on human skin samples the peptide reached the epidermis, used the skin's own calcium to form a gel, and helped dried-out, lipid-stripped skin hold water and stay less stiff. That reads more like a barrier and film effect than proof of new elastin being built. |
| Common Dosing | 2% of the commercial ingredient in a finished product Once or twice daily | About 4% of the ingredient solution in a finished product Once or twice daily |
| Administration | Topical (serums, creams) | Topical (serums, creams) |
| Typical Duration | About 2 months in the manufacturer's study before changes were measured; ongoing use to keep any effect | Manufacturer study ran one month; ongoing use for any maintained effect |
| Best Time to Take | Morning and/or evening, on clean skin before moisturizer | Morning and/or evening skincare routine |
Possible Side Effects May vary by individual |
|
|
| Research Summary | There is no independent, peer-reviewed clinical trial of palmitoyl tripeptide-38 on its own that we could find. The main human data is the manufacturer's: a placebo-controlled study in 25 women aged 42 to 70 with forehead lines and crow's feet, using 2% of the Matrixyl synthe'6 ingredient for two months, with reported reductions in wrinkle measures that ranged widely between people. Sederma's launch material in 2011 described visibly smoother forehead and crow's feet wrinkles after two months but gave no published sample sizes or numbers. Where the peptide shows up in published journals, it is usually as one ingredient in a multi-ingredient serum, which cannot isolate its effect. Broader reviews of cosmetic peptides make the same point about this whole category: results are often small, short and unpublished outside company brochures. A 2026 meta-analysis of randomized peptide trials found that topical peptides overall did not produce a significant wrinkle improvement in pooled data. Bottom line: a reasonable, well-tolerated ingredient with a plausible mechanism, but expect mild changes at best and treat the percentage claims as marketing until someone outside the company repeats them. | The best peer-reviewed work is a 2025 paper in ACS Applied Bio Materials (Ligorio and colleagues, with co-authors from Estee Lauder) that tracked the peptide in full-thickness human skin from a single donor. It showed penetration into the stratum corneum and epidermis, gel formation driven by calcium, reduced water loss and drying stress in delipidated skin (roughly comparable to 5 percent glycerol for drying stress), and stronger gels when mixed with collagen. Useful mechanistic data, but small samples and no living people. The appearance claims come from the manufacturer: a one-month, double-blind study in 10 women using 4 percent Biopeptide EL twice daily reported 33 percent better firmness and 20 percent better tone. That study is not in PubMed and is far too small to lean on. A separate 2023 trial of an elastin-like recombinant polypeptide built on the same VGVAPG repeat found improved elasticity after 28 days in 30 women, but that was a different molecule. Honest read: plausible biology, real skin penetration, no independent proof of visible results. |
Frequently Asked Questions: Palmitoyl Tripeptide-38 vs Palmitoyl Hexapeptide-12
What is the difference between Palmitoyl Tripeptide-38 and Palmitoyl Hexapeptide-12?
Palmitoyl Tripeptide-38 is a skin & hair peptide that palmitoyl tripeptide-38 is the active in sederma's matrixyl synthe'6, a newer member of the matrixyl family launched around 2011. it is a three-amino-acid fragment with a fatty acid tail, sold as a wrinkle 'filler from the inside' for forehead lines and crow's feet. it is a cosmetic ingredient, not a drug, and the honest picture is simple: the efficacy claims come almost entirely from the company that makes it. Palmitoyl Hexapeptide-12 is a skin & hair peptide that palmitoyl hexapeptide-12 is the six-amino-acid sequence vgvapg, a repeating piece of elastin, with a fatty acid tail attached so it can get into skin. it is sold under the trade name biopeptide el and pitched for firmness and elasticity, the bounce-back that fades with age. it is a cosmetic ingredient, not an fda-approved drug, and nobody has published an independent clinical trial showing it visibly changes skin. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Palmitoyl Tripeptide-38 or Palmitoyl Hexapeptide-12?
Neither is universally "better" - the choice depends on your specific goals. Palmitoyl Tripeptide-38 is typically used for skin & hair purposes, while Palmitoyl Hexapeptide-12 is used for skin & hair. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Palmitoyl Tripeptide-38 and Palmitoyl Hexapeptide-12 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Palmitoyl Tripeptide-38 and Palmitoyl Hexapeptide-12 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.